BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tiforbex submicron indomethacin regulatory update

Iroko said FDA accepted for review an NDA for Tiforbex submicron indomethacin to treat mild to moderate acute pain in adults. The company submitted the application in April;...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >